Search Results - Edna Chow Maneval

  • Showing 1 - 19 results of 19
Refine Results
  1. 1
    Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer

    Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer by Michael J. Pishvaian, Ignacio Garrido‐Laguna, Stephen V. Liu, Pratik S. Multani, Edna Chow‐Maneval, Christian Rolfo

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

    A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509 by James D. Joseph, Nhin Lu, Jing Qian, John Sensintaffar, Gang Shao, Dan Brigham, Michael Moon, Edna Chow Maneval, Isan Chen, Beatrice Darimont, Jeffrey H. Hager

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

    Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma by Bernard Escudier, Jan Roigas, Silke Gillessen, Ulrika Harmenberg, Sandhya Srinivas, Sasja F. Mulder, George Fountzilas, Christian Peschel, Per Flodgren, Edna Chow Maneval, Isan Chen, Nicholas J. Vogelzang

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

    Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Can... by Matthew R. Smith, Emmanuel S. Antonarakis, Charles J. Ryan, William L. Berry, Neal D. Shore, Glenn Liu, Joshi J. Alumkal, Celestia S. Higano, Edna Chow Maneval, Rajesh Bandekar, Carla J. de Boer, Margaret K. Yu, Dana E. Rathkopf

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone

    Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone by Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore, Ronald Tutrone, Joshi J. Alumkal, Charles J. Ryan, Mansoor N. Saleh, Ralph J. Hauke, Rajesh Bandekar, Edna Chow Maneval, Carla J. de Boer, Margaret K. Yu, Howard I. Scher

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

    Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer by Dana E. Rathkopf, Michael J. Morris, Josef J. Fox, Daniel C. Danila, Susan F. Slovin, Jeffrey H. Hager, Peter J. Rix, Edna Chow Maneval, Isan Chen, Mithat Gönen, Martin Fleisher, Steven M. Larson, Charles L. Sawyers, Howard I. Scher

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy

    Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy by Leonard B. Saltz, Lee S. Rosen, John L. Marshall, Robert J. Belt, Herbert I. Hurwitz, Sabine Eckhardt, Emily K. Bergsland, Daniel G. Haller, A. Craig Lockhart, Caio M. Rocha Lima, Xin Huang, Samuel E. DePrimo, Edna Chow‐Maneval, Richard C. Chao, Heinz Josef Lenz

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

    Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer by M. Dror Michaelson, Stéphane Oudard, Yen-Chuan Ou, L. Sengeløv, Fred Saad, Nadine Houede, Peter Ostler, Arnulf Stenzl, Gedske Daugaard, Robin L. Jones, Fredrik Laestadius, Anders Ullén, Amit Bahl, Daniel Castellano, Juergen Gschwend, Tristan Maurina, Edna Chow Maneval, Shaw-Ling Wang, María José Lechuga, Jolanda Paolini, Isan Chen

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

    Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001 by George D. Demetri, Luis Paz‐Ares, Anna F. Farago, Stephen V. Liu, Sant P. Chawla, Diégo Tosi, E.S. Kim, Collin M. Blakely, John C. Krauss, Darren Sigal, Lyudmila Bazhenova, Thomas John, Benjamin Besse, J. Wolf, Takashi Seto, Edna Chow‐Maneval, Pratik S. Multani, Ann Johnson, Brian Simmons, Robert C. Doebele

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

    OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) by Robert C. Doebele, Myung‐Ju Ahn, Salvatore Siena, Alexander Drilon, Matthew Krebs, Chung‐Wu Lin, Filippo de Braud, Thomas John, Daniel Shao-Weng Tan, Takashi Seto, Rafał Dziadziuszko, Hendrik‐Tobias Arkenau, Fabrice Barlési, Christian Rolfo, Juergen Wolf, Edna Chow‐Maneval, Pratik S. Multani, Na Cui, Todd Riehl, B.C. Cho

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

    Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer by Anna F. Farago, Long P. Le, Zongli Zheng, Alona Muzikansky, Alexander Drilon, Manish R. Patel, Todd M. Bauer, Stephen V. Liu, Sai‐Hong Ignatius Ou, David M. Jackman, Daniel B. Costa, Pratik S. Multani, Gary G. Li, Zachary Hornby, Edna Chow‐Maneval, David Luo, Jonathan E. Lim, A. John Iafrate, Alice T. Shaw

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide

    Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide by Dana E. Rathkopf, Matthew R. Smith, Charles J. Ryan, William R. Berry, Neal D. Shore, G. Liu, Celestia S. Higano, Joshi J. Alumkal, R. Hauke, Ronald Tutrone, Mansoor N. Saleh, Edna Chow Maneval, Shibu Thomas, Deborah Ricci, Margaret K. Yu, Carla J. de Boer, Angela Trinh, Thian Kheoh, Rajesh Bandekar, Howard I. Scher, Emmanuel S. Antonarakis

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> Isoforms

    ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> Isoforms by Kasey L. Couts, Judson Bemis, Jacqueline A. Turner, Stacey M. Bagby, Danielle Murphy, Jason Christiansen, Jennifer D. Hintzsche, Anh T. Le, Todd M. Pitts, Keith Wells, Allison Applegate, Carol M. Amato, Pratik S. Multani, Edna Chow‐Maneval, John J. Tentler, Yiqun G. Shellman, Matthew J. Rioth, Aik Choon Tan, René González, Theresa Medina, Robert C. Doebele, William A. Robinson

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor

    Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor by Christopher Alvarez‐Breckenridge, Julie J. Miller, Naema Nayyar, Corey M. Gill, Andrew Kaneb, Megan R. D’Andrea, Long P. Le, Jesse Lee, Ju Cheng, Zongli Zheng, William E. Butler, Pratik S. Multani, Edna Chow Maneval, Sun Ha Paek, Brian Toyota, Dora Dias‐Santagata, Sandro Santagata, Javier M. Romero, Alice T. Shaw, Anna F. Farago, Stephen Yip, Daniel P. Cahill, Tracy T. Batchelor, A. John Iafrate, Priscilla K. Brastianos

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

    What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) by Alexander Drilon, G. Li, Snjezana Doğan, Mrinal M. Gounder, Ronglai Shen, Maria E. Arcila, L. Wang, David M. Hyman, Jaclyn F. Hechtman, Wei Ge, Nicholas Cam, Jason Christiansen, Lu Wang, Edna Chow Maneval, Todd M. Bauer, Minesh Patel, Stephen V. Liu, S.-H.I. Ou, Anna F. Farago, Alice T. Shaw, Robert Shoemaker, J. K. Lim, Zachary Hornby, Pratik S. Multani, Marc Ladanyi, Manfred Berger, Nora Katabi, Ronald Ghossein, Alan L. Ho

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)

    Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG) by Ami V. Desai, Giles Robinson, Karen Gauvain, Ellen M. Basu, Margaret E. Macy, Luke Maese, Nicholas Whipple, Amit J. Sabnis, Jennifer H. Foster, Suzanne Shusterman, Janet Yoon, Brian Weiss, Mohamed S Abdelbaki, Amy E. Armstrong, Thomas F. Cash, Christine A. Pratilas, Nadège Corradini, Lynley V. Marshall, Mufiza Farid‐Kapadia, Saibah Chohan, Clare Devlin, Georgina Meneses‐Lorente, Alison K. Cardenas, Katherine E. Hutchinson, Guillaume Bergthold, Hubert Caron, Edna Chow Maneval, Amar Gajjar, Elizabeth Fox

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

    Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) by Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou, Manish R. Patel, Myung‐Ju Ahn, Jeeyun Lee, Todd M. Bauer, Anna F. Farago, Jennifer J. Wheler, Stephen V. Liu, Robert C. Doebele, Laura Giannetta, Giulio Cerea, Giovanna Marrapese, Michele Schirru, Alessio Amatu, Katia Bencardino, Laura Palmeri, Andrea Sartore‐Bianchi, Angelo Vanzulli, Sara Cresta, Silvia Damian, Matteo Duca, Elena Ardini, Gang Li, Jason Christiansen, Karey Kowalski, Ann Johnson, Rupal Patel, David Luo, Edna Chow‐Maneval, Zachary Hornby, Pratik S. Multani, Alice T. Shaw, Filippo de Braud

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

    Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials by Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko, Fabrice Barlési, Matthew Krebs, Alice T. Shaw, Filippo de Braud, Christian Rolfo, Myung‐Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R. Patel, Chao-Hua Chiu, Thomas John, Kōichi Goto, Christos S. Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu Li, Young Kwang Chae, Christine H. Chung, Gregory A. Otterson, Haruyasu Murakami, Chia‐Chi Lin, Daniel Shao-Weng Tan, Hans Prenen, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, Robert C. Doebele

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials by Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Salvatore Siena, Alice T. Shaw, Anna F. Farago, Collin M. Blakely, Takashi Seto, Byoung Chul Cho, Diégo Tosi, Benjamin Besse, Sant P. Chawla, Lyudmila Bazhenova, John C. Krauss, Young Kwang Chae, Minal Barve, Ignacio Garrido‐Laguna, Stephen V. Liu, Paul Conkling, Thomas John, Marwan Fakih, Darren Sigal, Herbert H. Loong, Gary L. Buchschacher, Pilar Garrido, Jorge J. Nieva, Conor Steuer, Tobias R. Overbeck, Daniel W. Bowles, Elizabeth Fox, Todd Riehl, Edna Chow‐Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, George D. Demetri

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: